Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.58 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | MLYCD | O95822 | 1/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19106102 | 0.88 | OPRD1 (0.48) | HSP90AA1HSP90AB1HPGDALDH1A1MAPT | |
| SCHEMBL5703500 | 0.85 | HPGD (0.73) | HSP90AA1HSP90AB1HPGDALDH1A1MAPT | |
| SCHEMBL13144179 | 0.85 | HPGD (0.54) | HSP90AA1HSP90AB1HPGDALDH1A1MAPT | |
| SCHEMBL18509298 | 0.85 | HPGD (0.54) | HSP90AA1HSP90AB1HPGDALDH1A1MAPT | |
| SCHEMBL21078118 | 0.85 | MLYCD (0.58) | HSP90AA1HSP90AB1HPGDMAPTMLYCD | |
| SCHEMBL8527824 | 0.85 | HPGD (0.58) | HSP90AA1HSP90AB1HPGDALDH1A1MAPT | |
| SCHEMBL8526980 | 0.83 | HPGD (0.56) | HSP90AA1HSP90AB1HPGDALDH1A1MAPT | |
| SCHEMBL10169810 | 0.83 | USP5 (0.47) | HSP90AA1HSP90AB1HPGDALDH1A1MAPT | |
| SCHEMBL18713522 | 0.83 | HPGD (0.56) | HSP90AA1HSP90AB1HPGDALDH1A1MAPT | |
| SCHEMBL23709482 | 0.81 | HPGD (0.49) | HSP90AA1HSP90AB1HPGDALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174470-A1 | COMPOUND AS A UBR BOX DOMAIN LIGAND | AUTOTAC INC. (KR) | 2023-06-08 | — | — | US | disclosed |
| US-20230174470-A1 | COMPOUND AS A UBR BOX DOMAIN LIGAND | AUTOTAC INC. (KR) | 2023-06-08 | — | — | US | disclosed |
| WO-2022149617-A1 | COMPOUND LIBRARY | 中外製薬株式会社 | 2022-07-14 | — | — | WO | disclosed |
| US-20220000883-A1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | EMORY UNIVERSITY | 2022-01-06 | — | — | US | disclosed |
| US-11077120-B2 | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto | EMORY UNIVERSITY (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200085837-A1 | Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto | UNIV EMORY (US) | 2020-03-19 | — | — | US | disclosed |
| US-10568889-B2 | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto | EMORY UNIVERSITY (US) | 2020-02-25 | — | — | US | disclosed |
| US-9750740-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | Kanos Pharmaceuticals, Inc. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170095476-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2017-04-06 | — | — | US | disclosed |
| US-20170042905-A1 | Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-02-16 | — | — | US | disclosed |
| CN-100345843-C | 4- (thioxanthene-9-subunit) -piperidine or acridine derivative and application thereof in preparation of medicines | BIOFRONTERA PHARMACEUTICALS GM (DE) | 2007-10-31 | — | — | CN | disclosed |
| US-7253158-B2 | Sulfonamides | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-20060183905-A1 | DERIVATIVES OF 4-(THIO-OR SELENOXANTHENE-9-YLIDENE)-PIPERIDINE OR ACRIDINE AND ITS USE AS A SELECTIVE 5-HT2B RECEPTOR ANTAGONIST | BIOFRONTERA BIOSCIENCE GMBH (DE) | 2006-08-17 | — | — | US | disclosed |
| US-7060711-B2 | Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist | BIOFRONTERA BIOSCIENCE GMBH (DE) | 2006-06-13 | — | — | US | disclosed |
| EP-1438307-B1 | DERIVATIVES OF 4-(THIO- OR SELENOXANTHENE-9-YLIDENE)-PIPERIDINE OR ACRIDINE AND ITS USE AS A SELECTIVE 5-HT2B RECEPTOR ANTAGONIST | BIOFRONTERA PHARMACEUTICALS GM (DE) | 2005-08-03 | — | — | EP | disclosed |
| CN-1575291-A | Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-ht2b receptor antagonist | BIOFRONTERA PHARMACEUTICALS GM (DE) | 2005-02-02 | — | — | CN | disclosed |
| EP-1438307-A2 | DERIVATIVES OF 4-(THIO- OR SELENOXANTHENE-9-YLIDENE)-PIPERIDINE OR ACRIDINE AND ITS USE AS A SELECTIVE 5-HT2B RECEPTOR ANTAGONIST | Biofrontera Pharmaceuticals GmbH (DE) | 2004-07-21 | — | — | EP | disclosed |
| US-20030166672-A1 | Derivatives of 4-(Thio- or Selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist | BIOFRONTERA BIOSCIENCE GMBH (DE) | 2003-09-04 | — | — | US | disclosed |
| EP-1306376-A1 | Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist | Biofrontera Pharmaceuticals AG (DE) | 2003-05-02 | — | — | EP | disclosed |
| WO-2003035646-A2 | DERIVATIVES OF 4-(THIO- OR SELENOXANTHENE-9-YLIDENE)-PIPERIDINE OR ACRIDINE AND ITS USE AS A SELECTIVE 5-HT2B RECEPTOR ANTAGONIST | BIOFRONTERA PHARMACEUTICALS GMBH (DE) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000883-A1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | PTGER2, PTGES2, PTGER1 | HSP90AA1 1602/4885HSP90AB1 2090/4885HPGD 141/4885 |
| US-11077120-B2 | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto | PTGER2, PTGES2, PTGES | HSP90AA1 1778/4885HSP90AB1 2115/4885HPGD 197/4885 |
| US-20170095476-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | HSP90AA1 584/4885HSP90AB1 856/4885HPGD 140/4885 |
| US-20030166672-A1 | Derivatives of 4-(Thio- or Selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist | HTR2B, HTR1B, HTR3B | HSP90AA1 495/4885HSP90AB1 297/4885HPGD 1620/4885 |
| US-20230174470-A1 | COMPOUND AS A UBR BOX DOMAIN LIGAND | UBR4, UBQLN2, UBTF | HSP90AA1 1154/4885HSP90AB1 814/4885HPGD 4033/4885 |
| US-20060183905-A1 | DERIVATIVES OF 4-(THIO-OR SELENOXANTHENE-9-YLIDENE)-PIPERIDINE OR ACRIDINE AND ITS USE AS A SELECTIVE 5-HT2B RECEPTOR ANTAGONIST | HTR2B, HTR1B, HTR3B | HSP90AA1 495/4885HSP90AB1 297/4885HPGD 1620/4885 |
| US-10568889-B2 | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto | PTGER2, PTGES2, PTGER1 | HSP90AA1 1602/4885HSP90AB1 2090/4885HPGD 141/4885 |
| US-20200085837-A1 | Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto | PTGER2, PTGES2, PTGER1 | HSP90AA1 1602/4885HSP90AB1 2090/4885HPGD 141/4885 |
| US-20170042905-A1 | Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto | PTGER2, PTGES2, PTGER1 | HSP90AA1 1602/4885HSP90AB1 2090/4885HPGD 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.